Circassia Pharmaceuticals (GB:NIOX) has released an update.
NIOX Group PLC, a leader in point-of-care asthma diagnosis, reports strong year-to-date performance and a healthy unaudited cash balance of £23.7m, up from £19.9m at year-end. The company, which recently settled claims for £0.4m, is preparing to release a mid-July trading update for the first half of 2024. NIOX continues its mission to enhance asthma management with its flagship NIOX VERO device, serving a global market through a combination of direct sales and distributors in 50 countries.
For further insights into GB:NIOX stock, check out TipRanks’ Stock Analysis page.
